Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Critical Reviews in Oncology/Hematology|February 5, 2021
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysisMelissa Bersanelli, Sebastiano Buti, Patrizia Giannatempo, et al.
Clinical Lung Cancer|March 25, 2021
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO TrialAlessandro Leonetti, Roberta Minari, Luca Boni, et al.
Tumori|June 4, 2026
Effectiveness of carboplatin vs cisplatin in lung cancer chemo-immunotherapy: A systematic review and meta-analysisAlessandro Leonetti, Giuseppe Maglietta, Marianna Peroni, et al.
Future Oncology (London, England)|February 4, 2021
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patientsMelissa Bersanelli, Diana Giannarelli, Alessandro Leonetti, et al.
Translational Lung Cancer Research|January 13, 2023
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic reviewMichela Verzè, Monica Pluchino, Alessandro Leonetti, et al.
Frontiers in Oncology|May 13, 2021
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature ReviewAlessandro Leonetti, Roberta Minari, Giulia Mazzaschi, et al.
Anti-Cancer Drugs|March 6, 2021
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinibRoberta Minari, Alessandro Leonetti, Letizia Gnetti, et al.
JTO Clinical and Research Reports|July 23, 2025
<i>BRAF</i> Fusion as Resistance Mechanism to Osimertinib in <i>EGFR</i>-Mutated NSCLC: A Case Report and Review of LiteratureMarianna Peroni, Alessandro Leonetti, Roberta Minari, et al.
Cells|July 2, 2021
Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIsAlessandro Leonetti, Mjriam Capula, Roberta Minari, et al.
Tumori|September 29, 2021
Transient asymptomatic pulmonary opacities and interstitial lung disease in <i>EGFR</i>-mutated non-small cell lung cancer treated with osimertinibGianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall'Olio, et al.
Pageof 7